FundaciÃ³n JimÃ©nez Diaz Trials

FundaciÃ³n JimÃ©nez Diaz	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Guerrero, Tatiana Hernandez

KEYNOTE F82, NCT06205706: BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors

Sep 2024 - Sep 2024 : Data from Part A of P1 portion of the trial studying BI-1910 as single agent for adv solid tumors

Recruiting

1/2

104

Europe, US

BI-1910, Pembrolizumab

BioInvent International AB, Merck Sharp & Dohme LLC

Solid Tumors, Non Small Cell Lung Cancer, Hepatocellular Carcinoma

07/27

11/28

H-200-001, NCT04180215 / 2019-000907-34: A Phase 1/2 Study in Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

Active, not recruiting

1/2

200

Europe, US

HB-201 intravenous administration., HB-202 intravenous administration alternating with HB-201 intravenous administration., HB-201 intravenous administration + standard of care regimen including pembrolizumab., HB-202 / HB-201 alternating intravenous administration + pembrolizumab., HB-202 / HB-201 alternating intravenous administration + standard of care regimen including pembrolizumab., HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C)

Hookipa Biotech GmbH, Hookipa Biotech

HPV-Related Squamous Cell Carcinoma

06/25

06/26

METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Recruiting

1/2

576

Europe, US, RoW

MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy

Merus N.V.

Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer

03/26

03/27

TNG462-C101, NCT05732831: Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

Recruiting

1/2

225

Europe, US

TNG462, Pembrolizumab, Keytruda

Tango Therapeutics, Inc.

Locally Advanced Solid Tumor

05/26

09/26

NCT05072106: Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors

Recruiting

Europe

Lurbinectedin, PM01183, Bosentan

PharmaMar

Advanced Solid Tumor

10/22

11/22

PROCEADE-CRC-01, NCT05464030: Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors

Recruiting

200

Europe, Canada, Japan, US, RoW

M9140, Precemtabart tocentecan, Bevacizumab, Capecitabine, 5-fluorouracil (5-FU), Folinic acid

EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany

Colorectal Cancer

02/26

ELVN-002-003, NCT06328738: ELVN-002 with Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

Recruiting

275

Europe, US, RoW

ELVN-002, Trastuzumab, 5-Fluorouracil, Oxaliplatin, Capecitabine, Eribulin, paclitaxel, Leucovorin

Enliven Therapeutics

HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification, Colorectal Cancer

01/27

07/28

NCT06421935: M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)

Recruiting

Europe, Japan, US, RoW

M9466, HRS-1167;, Tuvusertib, Substance code MSC2584415A; also known as M1774, VXc-400, or VR 1363004, Abiraterone acetate, Abiraterone, Prednisone/Prednisolone

EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany

Advanced Solid Tumor

03/26

MOONRAY-01, NCT06586515: , A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Recruiting

540

Europe, Canada, Japan, US

LY3962673, Cetuximab, Gemcitabine, nab-paclitaxel, Oxaliplatin, leucovorin, Irinotecan, 5-fluorouracil

Eli Lilly and Company, Loxo Oncology, Inc.

Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer

03/29

NCT05101265: Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment

Recruiting

Europe

Lurbinectedin, PM1183

PharmaMar

Advanced Solid Tumor, Hepatic Impairment

06/25

TOS-358-001, NCT05683418: A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors

Recruiting

241

Europe, US

TOS-358

Totus Medicines

Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Endometrial Cancer, HR+/HER2-negative Breast Cancer

12/25

NCT05242822: A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

Terminated

Europe, US, RoW

KIN-3248

Kinnate Biopharma

Solid Tumor, Adult, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma

10/24

ELVN-002-001, NCT05650879: ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

Recruiting

198

Europe, US, RoW

ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Enhertu, T-DXd, Trastuzumab emtansine, Kadcyla, T-DM1

Enliven Therapeutics

HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification

07/26

Lubomirov, Rubin

NCT05072106: Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors

Recruiting

Europe

Lurbinectedin, PM01183, Bosentan

PharmaMar

Advanced Solid Tumor

10/22

11/22

NCT05063318: Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors

Recruiting

Europe

Lurbinectedin alone, Lurbinectedin+Itraconazole co-administration

PharmaMar

Advanced Solid Tumors

11/22

12/22

NCT05101265: Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment

Recruiting

Europe

Lurbinectedin, PM1183

PharmaMar

Advanced Solid Tumor, Hepatic Impairment

06/25

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Guerrero, Tatiana Hernandez

KEYNOTE F82, NCT06205706: BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors

Sep 2024 - Sep 2024 : Data from Part A of P1 portion of the trial studying BI-1910 as single agent for adv solid tumors

Recruiting

1/2

104

Europe, US

BI-1910, Pembrolizumab

BioInvent International AB, Merck Sharp & Dohme LLC

Solid Tumors, Non Small Cell Lung Cancer, Hepatocellular Carcinoma

07/27

11/28

H-200-001, NCT04180215 / 2019-000907-34: A Phase 1/2 Study in Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers

Active, not recruiting

1/2

200

Europe, US

Hookipa Biotech GmbH, Hookipa Biotech

HPV-Related Squamous Cell Carcinoma

06/25

06/26

METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Recruiting

1/2

576

Europe, US, RoW

MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy

Merus N.V.

Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer

03/26

03/27

TNG462-C101, NCT05732831: Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

Recruiting

1/2

225

Europe, US

TNG462, Pembrolizumab, Keytruda

Tango Therapeutics, Inc.

Locally Advanced Solid Tumor

05/26

09/26

NCT05072106: Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors

Recruiting

Europe

Lurbinectedin, PM01183, Bosentan

PharmaMar

Advanced Solid Tumor

10/22

11/22

PROCEADE-CRC-01, NCT05464030: Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors

Recruiting

200

Europe, Canada, Japan, US, RoW

M9140, Precemtabart tocentecan, Bevacizumab, Capecitabine, 5-fluorouracil (5-FU), Folinic acid

EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany

Colorectal Cancer

02/26

ELVN-002-003, NCT06328738: ELVN-002 with Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

Recruiting

275

Europe, US, RoW

ELVN-002, Trastuzumab, 5-Fluorouracil, Oxaliplatin, Capecitabine, Eribulin, paclitaxel, Leucovorin

Enliven Therapeutics

HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification, Colorectal Cancer

01/27

07/28

NCT06421935: M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)

Recruiting

Europe, Japan, US, RoW

M9466, HRS-1167;, Tuvusertib, Substance code MSC2584415A; also known as M1774, VXc-400, or VR 1363004, Abiraterone acetate, Abiraterone, Prednisone/Prednisolone

EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany

Advanced Solid Tumor

03/26

MOONRAY-01, NCT06586515: , A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Recruiting

540

Europe, Canada, Japan, US

LY3962673, Cetuximab, Gemcitabine, nab-paclitaxel, Oxaliplatin, leucovorin, Irinotecan, 5-fluorouracil

Eli Lilly and Company, Loxo Oncology, Inc.

Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer

03/29

NCT05101265: Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment

Recruiting

Europe

Lurbinectedin, PM1183

PharmaMar

Advanced Solid Tumor, Hepatic Impairment

06/25

TOS-358-001, NCT05683418: A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors

Recruiting

241

Europe, US

TOS-358

Totus Medicines

Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Endometrial Cancer, HR+/HER2-negative Breast Cancer

12/25

NCT05242822: A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

Terminated

Europe, US, RoW

KIN-3248

Kinnate Biopharma

Solid Tumor, Adult, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma

10/24

ELVN-002-001, NCT05650879: ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

Recruiting

198

Europe, US, RoW

ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Enhertu, T-DXd, Trastuzumab emtansine, Kadcyla, T-DM1

Enliven Therapeutics

HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification

07/26

Lubomirov, Rubin

NCT05072106: Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors

Recruiting

Europe

Lurbinectedin, PM01183, Bosentan

PharmaMar

Advanced Solid Tumor

10/22

11/22

NCT05063318: Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors

Recruiting

Europe

Lurbinectedin alone, Lurbinectedin+Itraconazole co-administration

PharmaMar

Advanced Solid Tumors

11/22

12/22

NCT05101265: Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment

Recruiting

Europe

Lurbinectedin, PM1183

PharmaMar

Advanced Solid Tumor, Hepatic Impairment

06/25



	Diseases Companies Products Productz Mechanisms of Action Sites